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Introduction
Antibodies to cytotoxic T-lymphocyte-associated protein
4 (CTLA4) potentiate an immune response against can-
cer. Response rates in melanoma patients are range
from 10 to 19%[1]. To increase the efficacy and variety
of cancer types treated by anti CTLA4, a combination
therapy should be pursued. RG7787 is a recombinant
immunotoxin composed of an anti-mesothelin Fab fused
to a fragment of Pseudomonas exotoxin A (PE). RG7787
is currently tested in phase 1 trials for mesothelin
expressing malignancies. We previously observed that
an anti-mesothelin immunotoxin produced major tumor
regressions in humans with advanced mesothelioma
when combined with Cytoxan and Pentostatin appar-
ently due to T cell activation[2] and we are exploring
other ways to activate the immune system when cells
are killed by immunotoxin. We hypothesize that com-
bining RG7787 with anti CTLA4 will promote activation
of the immune system and cancer elimination.
Methods
We transfected the 66C14 mouse breast cancer cell line
with human mesothelin and grew the cancer cells in
immune-competent BALB/c mice that express a human
mesothelin transgene so that they will not reject the
tumors. The transfected cells are killed by RG7787 in
cell culture (IC50 12 ng/ml). Anti-tumor activity was
evaluated by intra tumoral-injection of RG7787 com-
bined with intra-peritoneal injection of anti CTLA4.
Results
We found that combining RG7787 with anti CTLA4
produced a 76% complete remission (CR) rate, while CR
was reached in only 15% of the mice under anti CTLA4
monotherapy. The survival benefit was statistically sig-
nificantly (P= 0.0012). No mice reached CR after treat-
ment with RG7787 alone or in the PBS treated controls.
Furthermore, re-challenging of the mice that reached
CR with the parental cell line (66C14 without human
mesothelin) resulted in complete rejection of the tumor
in all the mice. We also found treatment with antibodies
to CD8 decreased the CR rate to 12%, indicating that
CD8+ T cells are necessary for the response.
Conclusions
Combining RG7787 with anti CTLA4 produces a high
rate of complete remissions in a breast cancer model.
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